Takeda's R&D chief Andy Plump to retire; Novo Nordisk appoints global research head

RegulatoryapprovedNeutral

AI Analysis

Summary

Takeda's R&D chief Andy Plump will retire in June 2027 after leading the division since 2018, as the company celebrates FDA approvals. Novo Nordisk has appointed a new global research head.

Outcome Details

Takeda received a pair of FDA approvals

Importance:3/10

Sentiment:

0.20

management changeretirementFDA approvalR&D leadership

Related Companies

$TAK $NVO $SNY

Read the original article

Published by Endpoints News on September 11, 2026 11:00 AM

Read Original